Advertisement
Advertisement

HIV Care Today


Poll: At $14,105/Year, Is Dolutegravir Fairly Priced?
By Paul E. Sax, M.D.
August 28, 2013

The recently approved once-daily integrase inhibitor dolutegravir is now in pharmacies and, like every new HIV drug, the price -- around $14k/year -- has generated some controversy.

Read more …


Dolutegravir Approval Signals a Beginning and the End of Something Very Special
By Paul E. Sax, M.D.
August 12, 2013

As anticipated, the FDA approved dolutegravir today for HIV treatment, the third integrase inhibitor now available.

This was about as surprising as the arrival of Royal Baby Prince George. We knew dolutegravir was coming soon, just not exactly when or what it would be named.

Read more …


What Can We Look Forward to in HIV Cure Research?
By Nelson Vergel, B.S.Ch.E., M.B.A.
July 15, 2013

Part two of a two-part conversation with research advocate Richard Jefferys, who coordinates the Basic Science Vaccines and Prevention Project at Treatment Action Group in New York City.

Read more …


What's New and Notable in HIV Cure Research?
By Nelson Vergel, B.S.Ch.E., M.B.A.
July 15, 2013

Part one of a two-part conversation with research advocate Richard Jefferys, who coordinates the Basic Science Vaccines and Prevention Project at Treatment Action Group in New York City.

Read more …


Enough With the HIV Treatment Cascade Research, Let's Do Something About It Already
By Lisa Fitzpatrick, M.D., M.P.H.
June 7, 2013

If I hear or read another proclamation about the "HIV treatment cascade" and the need for more research to understand engagement in care, I am going to scream! There, I said it. It seems this cascade -- described initially by Laura Cheever at HRSA and most recently and formally by Gardner and colleagues -- has taken the HIV world by storm. It has captivated the field of HIV practitioners, advocates, researchers and scientists and peppers nearly every lecture at conferences and conversation at the watercooler. But why?

Read more …


HIV Opportunistic Infection Guidelines Updated
By Paul E. Sax, M.D.
May 8, 2013

Some very hard-working folks at the NIH, CDC and IDSA have updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, which are available for review here.

As with the previous versions (the prior iteration is from 2009), the OI Guidelines are comprehensive, exhaustively referenced (184 references for TB alone!), and authoritative. Note that the PDF version weighs in at 416 pages, so I doubt many people will be printing this out and carrying it around in their white coats. Fortunately, for the first time these Guidelines are also available in their entirety online in an HTML version, which is undoubtedly how most will access them, and certainly make them easier to update.

Read more …


MyHIVclinic.org: Rethinking How We Learn to Practice HIV Medicine
By Benjamin Young, M.D., Ph.D.
May 6, 2013

Less than 20 years ago, when I started doing HIV/AIDS care, most of my patients died within a year or two of their diagnosis. Medications were only marginally effective and caused side effects (or even death), and the notion of long-term survival was only a hope. To discuss a normal life expectancy was wishful thinking, perhaps false hope.

Read more …


How to Interpret Medical Breakthroughs in the Mainstream Media
By Paul E. Sax, M.D.
May 2, 2013

There it is, right in your daily paper, on your tablet or computer screen, or wherever you get your news today -- a headline about a great medical breakthrough everyone's been waiting for:

Scientists on Brink of HIV Cure
Researchers believe that there will be a breakthrough in finding a cure for HIV "within months."

Yes, I read this exact headline recently.

Read more …


Lost and Found: Helping Patients Develop Emotional Resilience
By David Fawcett, Ph.D., L.C.S.W.
April 30, 2013

Widespread publication of the treatment cascade has heightened the level of concern for engaging and retaining patients in HIV care. A significant percentage of persons living with HIV are unaware of their status, and an astonishingly low number of people have successfully suppressed their viral loads. Despite recent articles that have reported potential variation in these calculations, it is clear that a significant number of people remain out of care, marginally engaged or worse.

Read more …


Data Safety Monitoring Board Closes HIV Vaccine Study -- the End of Adenovirus as a Vaccine Vector?
By Paul E. Sax, M.D.
April 29, 2013

On Friday, the NIH announced that HVTN 505, a clinical trial of an HIV vaccine using an adenovirus vector, would be stopped based on a finding of futility by an independent DSMB.

Read more …

 < Prev  |  1  |  2  |  3  |  4  |  5  |  …  |  14  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement